Development and validation of an RNA sequencing-based classifier for medullary thyroid carcinoma on thyroid FNA.
作者信息
Lubin Daniel J, Sadow Peter M
机构信息
Department of Pathology, Emory University Hospital Midtown, Atlanta, GA, USA.
Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
出版信息
Cancer Cytopathol. 2023 Mar;131(3):154-157. doi: 10.1002/cncy.22643. Epub 2022 Sep 1.
Abstract
摘要
相似文献
1
Development and validation of an RNA sequencing-based classifier for medullary thyroid carcinoma on thyroid FNA.基于RNA测序的甲状腺细针穿刺活检中甲状腺髓样癌分类器的开发与验证
Cancer Cytopathol. 2023 Mar;131(3):154-157. doi: 10.1002/cncy.22643. Epub 2022 Sep 1.
2
Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier.术前识别甲状腺髓样癌（MTC）： Afirma MTC RNA 测序分类器的临床验证。
Thyroid. 2022 Sep;32(9):1069-1076. doi: 10.1089/thy.2022.0189. Epub 2022 Aug 8.
3
Diagnostic pitfall of thyroid fine-needle aspiration induced fibrosis: follicular adenoma mimicking medullary thyroid carcinoma in frozen section.甲状腺细针抽吸诱导纤维化的诊断陷阱：冰冻切片中模仿甲状腺髓样癌的滤泡性腺瘤。
Diagn Pathol. 2021 Mar 17;16(1):25. doi: 10.1186/s13000-021-01087-2.
4
Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review.使用细针穿刺降钙素检测甲状腺髓样癌：一项系统评价。
Diagn Cytopathol. 2016 Jan;44(1):45-51. doi: 10.1002/dc.23375. Epub 2015 Oct 19.
5
Limitations of preoperative cytology for medullary thyroid cancer: Proposal for improved preoperative diagnosis for optimal initial medullary thyroid carcinoma specific surgery.术前细胞学检查对甲状腺髓样癌的局限性：为优化初始甲状腺髓样癌特异性手术提出的改进术前诊断建议。
Head Neck. 2021 Mar;43(3):920-927. doi: 10.1002/hed.26550. Epub 2020 Dec 2.
6
Thyroid Tumors You Don't Want to Miss.不容错过的甲状腺肿瘤。
Surg Pathol Clin. 2019 Dec;12(4):901-919. doi: 10.1016/j.path.2019.08.008.
7
Optimizing Diagnostic Accuracy of Fine Needle Aspiration Biopsy Calcitonin Measurements in Detecting Medullary Thyroid Carcinoma.优化细针穿刺活检降钙素测量在检测甲状腺髓样癌中的诊断准确性。
Thyroid. 2024 Feb;34(2):186-196. doi: 10.1089/thy.2023.0313. Epub 2024 Jan 12.
8
Cytologic diagnosis of medullary thyroid carcinoma in the Asia-Pacific region.亚太地区甲状腺髓样癌的细胞学诊断。
Diagn Cytopathol. 2021 Jan;49(1):60-69. doi: 10.1002/dc.24586. Epub 2020 Aug 22.
9
The essential use of FNA-calcitonin for detecting medullary thyroid cancer.细针穿刺抽吸活检检测降钙素在甲状腺髓样癌诊断中的重要应用。
Endocrine. 2014 Sep;47(1):342-4. doi: 10.1007/s12020-014-0226-x. Epub 2014 Mar 8.
10
Head-to-head comparison of FNA cytology vs. calcitonin measurement in FNA washout fluids (FNA-CT) to diagnose medullary thyroid carcinoma. A systematic review and meta-analysis.细针穿刺细胞学检查（FNAC）与细针穿刺洗脱液降钙素（FNA-CT）检测对头颈转移性髓样甲状腺癌的诊断价值：系统评价和荟萃分析。
Endocrine. 2022 Jan;75(1):33-39. doi: 10.1007/s12020-021-02892-x. Epub 2021 Oct 4.
引用本文的文献
1
External Validation of a Predictive Model for Thyroid Cancer Risk with Decision Curve Analysis.基于决策曲线分析的甲状腺癌风险预测模型的外部验证
Diagnostics (Basel). 2025 Mar 11;15(6):686. doi: 10.3390/diagnostics15060686.
本文引用的文献
1
Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier.术前识别甲状腺髓样癌（MTC）： Afirma MTC RNA 测序分类器的临床验证。
Thyroid. 2022 Sep;32(9):1069-1076. doi: 10.1089/thy.2022.0189. Epub 2022 Aug 8.
2
Distant metastasis in medullary thyroid carcinoma: Clinical outcomes and implications of T stage.甲状腺髓样癌的远处转移：T 分期的临床结果和意义。
Clin Endocrinol (Oxf). 2022 Nov;97(5):676-684. doi: 10.1111/cen.14717. Epub 2022 Apr 5.
3
Thyroid nodule molecular profiling: The clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifier-suspicious results.甲状腺结节分子分析：Afirma Xpression Atlas 在 Afirma 基因组测序分类器可疑结果的结节中的临床应用。
Surgery. 2022 Jan;171(1):155-159. doi: 10.1016/j.surg.2021.08.058.
4
Comparison of Afirma GEC and GSC to Nodules Without Molecular Testing in Cytologically Indeterminate Thyroid Nodules.在甲状腺细针穿刺结果不确定的结节中，将Afirma基因表达分类（GEC）和基因组测序分类（GSC）与未进行分子检测的结节进行比较。
J Endocr Soc. 2021 Oct 7;5(11):bvab148. doi: 10.1210/jendso/bvab148. eCollection 2021 Nov 1.
5
Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.在细胞学不确定的甲状腺结节中，Afirma 基因测序分类器与基因表达分类器的性能比较。
J Am Soc Cytopathol. 2022 Mar-Apr;11(2):74-78. doi: 10.1016/j.jasc.2021.07.002. Epub 2021 Jul 22.
6
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.普拉替尼治疗晚期或转移性 RET 改变型甲状腺癌（ARROW）患者的多队列、开放标签、注册、1/2 期研究。
Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501. doi: 10.1016/S2213-8587(21)00120-0. Epub 2021 Jun 9.
7
Cytology versus calcitonin assay in fine-needle aspiration biopsy wash-out fluid (FNAB-CT) in diagnosis of medullary thyroid microcarcinoma.细胞学与降钙素测定在细针抽吸活检洗脱液（FNAB-CT）中的应用对诊断甲状腺髓样微癌的价值。
Endocrine. 2021 Nov;74(2):340-348. doi: 10.1007/s12020-021-02759-1. Epub 2021 May 24.
8
Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.连续 Bethesda III-VI 甲状腺结节中的 Afirma 基因组测序分类器和 Xpression Atlas 分子检测结果。
J Clin Endocrinol Metab. 2021 Jul 13;106(8):2198-2207. doi: 10.1210/clinem/dgab304.
9
Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.单中心经验应用 Afirma 和 Thyroseq 检测在甲状腺结节不明确病例。
Thyroid. 2021 Sep;31(9):1376-1382. doi: 10.1089/thy.2020.0801. Epub 2021 Apr 29.
10
Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.分子检测技术在诊断甲状腺结节中的有效性：一项随机临床试验。
JAMA Oncol. 2021 Jan 1;7(1):70-77. doi: 10.1001/jamaoncol.2020.5935.
Zotero 插件